14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
ASMB vs DBVT
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ASMB vs DBVT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ASMB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–3 Matrix Metrics)
ASMB Overall Winner
6-Pillar Tally: ASMB 4 – 2 DBVT
Matrix Metrics: ASMB 6 – 3 DBVT
As of Nov 16, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ASMB carries a Unified Composite Score of 42.6/100 (HOLD) at $21.46 (N/M Forward P/E, -31.8% operating margin), whereas DBVT carries 30.9/100 (SELL) at $10.26 (N/M Forward P/E, -5577.0% operating margin).
Growth vs. Quality Trade-Off: ASMB earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. DBVT 30.9/100 SELL) and 1.08β · 59% Vol risk profile, whereas DBVT leads top-line expansion (-42.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
ASMB
NASDAQ
Head-to-Head Winner
Assembly Biosciences, Inc
Pharmaceutical Preparations
Market Cap
$414.5M
TTM Revenue
$67M
Forward P/E
N/M
Beta / 30D Vol
1.08β · 59% Vol
Unified Composite Score
42.6 / 100
HOLD
Tech 40.0
Fund 48.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.1 · SMA20: $20.56 · SMA50: $22.95
DBVT
NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
Market Cap
$682.5M
TTM Revenue
$3.7M
Forward P/E
N/M
Beta / 30D Vol
1.17β · 77% Vol
Unified Composite Score
30.9 / 100
SELL
Tech 15.0
Fund 36.0
Flow 60.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $10.28 · SMA50: $10.78
6-Pillar Scorecard Institutional Category Breakdown (ASMB 4 – 2 DBVT)
Columns: Metric · ASMB · DBVT
1. Valuation Multiples
ASMB
Forward P/E
N/M
N/M
Trailing P/E
19.6x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
6.2x
140.3x
2. Growth & Scale
DBVT
Revenue Growth (YoY)
-72.6%
-42.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$67M
$3.7M
Market Cap
$414.5M
$682.5M
3. Profitability & Quality
ASMB
Gross Margin
3.3%
100.0%
Operating Margin
-31.8%
-5577.0%
Net Profit Margin
-16.6%
0.0%
Return on Equity (ROE)
-4.6%
-205.8%
4. Balance Sheet & Cash Flow
ASMB
Cash Generation (TTM)
-$21M EBITDA
-$192M
Cash Flow Margin
-31.7% EBITDA Mgn
N/A
Net Cash / Leverage
$14.67 Book/Sh · -4.6% ROE
$158M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DBVT
Options Structure Phase
UNCLASSIFIED
SURGE
Current IV / %ile
109.3% (100th %ile)
64.5% (13th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
ASMB
OpEx & R&D Intensity
35.1% of Rev ($24M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ASMB (6) vs DBVT (3)
Institutional Metric
ASMB
DBVT
Criterion
Row Edge
Market Capitalization
Scale
$414.5M
$682.5M
Larger Scale
DBVT
Trailing P/E Ratio
Valuation
19.6x
N/M
Lower Multiple
ASMB
Forward P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Revenue Growth (YoY)
Growth
-72.6%
-42.9%
Higher Growth
DBVT
Operating Margin (TTM)
Profitability
-31.8%
-5577.0%
Higher Margin
ASMB
Net Profit Margin
Profitability
-16.6%
0.0%
Higher Margin
DBVT
Return on Equity (ROE)
Capital Efficiency
-4.6%
-205.8%
Higher ROE
ASMB
52-Week Range Position
Momentum
11% ($19–$40)
9% ($9–$26)
Stronger Trend
ASMB
Beta / 30D Volatility
Risk Regime
1.08β · 59% Vol
1.17β · 77% Vol
Lower Realized Risk
ASMB
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD)
30.9 / 100 (SELL)
Higher Composite
ASMB
Trailing 12M Revenue (USD)
Operating Scale
$67M
$3.7M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.3%
100.0%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev
N/M PEG · 140.3x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA ($14.67 Book/Sh · -4.6% ROE)
-$192M ($158M Net Cash)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
DBVT +6.53 pp
ASMB:
+6.84%
·
DBVT:
+13.37%
3M Horizon
DBVT +4.1 pp
ASMB:
-33.19%
·
DBVT:
-29.09%
6M Horizon
ASMB +23.56 pp
ASMB:
-21.72%
·
DBVT:
-45.28%
1Y Horizon
DBVT +18.13 pp
ASMB:
-39.57%
·
DBVT:
-21.44%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ASMB vs DBVT. Trailing 12-month operating profitability (ASMB -31.8% vs DBVT -5577.0%) and valuation multiples (ASMB N/M vs DBVT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
ASMB ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $67M
Gross Margin 3.3%
Op. Margin -31.8%
ROE / Fwd P/E -4.6% · N/M
DBVT ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $3.7M
Gross Margin 100.0%
Op. Margin -5577.0%
ROE / Fwd P/E -205.8% · N/M
ASMB
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
109.3%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
DBVT
SURGE
5d in phase · OBV ACCUMULATION
Current IV
64.5%
IV Percentile
13th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
ASMB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $414.5M market capitalization and -31.8% operating margin.
OpEx & R&D Reinvestment
35.1% of Rev ($24M)
90D Engineering Disclosures
0 Published
DBVT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $682.5M market capitalization and -5577.0% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ASMB vs DBVT Key Questions & Quantitative Answers
Is ASMB or DBVT a better stock to buy right now?
As of Nov 16, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ASMB carries a Unified Composite Score of 42.6/100 (HOLD) at $21.46 (N/M Forward P/E, -31.8% operating margin), whereas DBVT carries 30.9/100 (SELL) at $10.26 (N/M Forward P/E, -5577.0% operating margin). Growth vs. Quality Trade-Off: ASMB earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. DBVT 30.9/100 SELL) and 1.08β · 59% Vol risk profile, whereas DBVT leads top-line expansion (-42.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Does ASMB or DBVT have stronger revenue and earnings growth?
DBVT leads the Growth & Scale pillar: ASMB posts -72.6% YoY revenue growth and +0.0% YoY earnings growth on $67M TTM revenue (3.3% gross margin, -31.8% operating margin), compared with DBVT at -42.9% YoY revenue growth and +0.0% YoY earnings growth on $3.7M TTM revenue (100.0% gross margin, -5577.0% operating margin). On trailing 12-month operating scale, ASMB generates $67M in USD-normalized revenue versus $3.7M for DBVT. In operating R&D and SG&A reinvestment, ASMB deploys 35.1% of Rev ($24M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DBVT.
Is ASMB or DBVT cheaper on valuation?
ASMB screens cheaper on headline valuation multiples. ASMB trades at N/M Forward P/E, 19.6x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-31.7% EBITDA margin), whereas DBVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 140.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ASMB (-4.6% ROE) versus DBVT (-205.8% ROE) capital efficiency.
How is options market volatility positioned on ASMB vs DBVT?
In options market volatility and institutional positioning, ASMB carries 109.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.08β · 59% Vol realized risk). By comparison, DBVT carries 64.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.17β · 77% Vol realized risk).
Assembly Biosciences, Inc (ASMB) Research Suite
DBV Technologies S.A. (DBVT) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.